NCT01406119View on ClinicalTrials.gov

An Extension Study of ABT-806 in Subjects With Advanced Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

October 31, 2011

Primary Completion Date

January 31, 2017

Study Completion Date

January 31, 2017

Conditions
Advanced Solid Tumors
Interventions
DRUG

ABT-806

ABT-806 will be administered by intravenous infusion.

Trial Locations (4)

3084

Site Reference ID/Investigator# 60619, Heidelberg

4029

Site Reference ID/Investigator# 63845, Herston

21231

Site Reference ID/Investigator# 58883, Baltimore

02215

Site Reference ID/Investigator# 58882, Boston

All Listed Sponsors
lead

AbbVie (prior sponsor, Abbott)

INDUSTRY

NCT01406119 - An Extension Study of ABT-806 in Subjects With Advanced Solid Tumors | Biotech Hunter | Biotech Hunter